Novakand Pharma AB (FRA:3EE0) Total Receivables: €0.04 Mil (As of Dec. 2025)


What is Novakand Pharma AB Total Receivables?

Novakand Pharma AB FRA:3EE0 Total Receivables is €0.04 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Novakand Pharma AB's Total Receivables for the quarter that ended in Dec. 2025 was €0.04 Mil.

Novakand Pharma AB Total Receivables Related Terms

Novakand Pharma AB Total Receivables Historical Data

* Premium members only.

The historical data trend for Novakand Pharma AB's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novakand Pharma AB Total Receivables Chart

Novakand Pharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.25 0.25 0.03 0.04 0.04

Novakand Pharma AB Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.11 0.06 0.06 0.04

Novakand Pharma AB Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of €0.04 Mil mean?
Novakand Pharma AB (FRA:3EE0) has a Total Receivables of €0.04 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Novakand Pharma AB and its competitors.
Is Novakand Pharma AB's Total Receivables too high?
Novakand Pharma AB's current Total Receivables is €0.04 Mil.
How does Novakand Pharma AB's Total Receivables compare to VRTX and REGN?
Novakand Pharma AB's Total Receivables of €0.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Novakand Pharma AB and its competitors. Novakand Pharma AB's current Total Receivables is €0.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novakand Pharma AB stock overvalued right now?
Novakand Pharma AB (FRA:3EE0) has a current Total Receivables of €0.04 Mil. The current Total Receivables is €0.04 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Novakand Pharma AB (FRA:3EE0), the current Total Receivables is €0.04 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Novakand Pharma AB Business Description

Address Nanna Svarts vag 4, Solna, SWE, 171 65
Novakand Pharma AB is developing a new class of innovative drugs focusing on inflammatory diseases and cancer. The company is developing a new class of small molecule drugs that control disease promoting immune cells with precision, by targeting the fractalkine axis.